[Clinical and fundamental study of guanabenz in hypertensive patients with renal failure].
Clinical and fundamental study of Guanabenz were performed in 20 hypertensive patients with renal failure, who were treated by maintenance hemodialysis treatment. The patients received 2 mg of Guanabenz orally, twice a day for 3 months or more. The clinical efficacy of good control was attained in 65%, and of fair control in 90%. On the other hand, the objective and subjective effects of Guanabenz were compared between short term (within one year long) hemodialysis patients and long term (over one year) patients. The overall clinical efficacy was higher in short term patients. The serum level of Guanabenz in hemodialysis patients showed a maximum value at 2-4 hours after administration. As Guanabenz might not be removed so much by hemodialysis, the administration schedule and daily dosage were discussed. There were no severe side effects arising from administration of Guanabenz.
Nishio
S
S
Department of Urology, Seichokai Fuchu Hospital.
Hayashi
S
S
Yoshihara
H
H
D000328:Adult; D000368:Aged; D005260:Female; D006143:Guanabenz / Q000493:pharmacokinetics / Q000627:therapeutic use*; D006146:Guanidines / Q000627:therapeutic use*; D006801:Humans; D006973:Hypertension / Q000188:drug therapy*; D007676:Kidney Failure, Chronic / Q000150:complications*; D008297:Male; D008875:Middle Aged; D006435:Renal Dialysis
D006146:Guanidines; D006143:Guanabenz